Intracerebral hemorrhage (ICH) leads to high rates of death and disability. The pronounced infl ammatory reactions that rapidly follow ICH contribute to disease progression. Our recent clinical trial demonstrated that oral administration of an immune modulator fingolimod restrained secondary injury derived from initial hematoma, but the mechanisms remain unknown. In this study, we aim to investigate the effects of fingolimod on inflammatory mediators and vascular permeability in the clinical trial of oral fingolimod for intracerebral hemorrhage (ICH). The results showed that fingolimod decreased the numbers of circulating CD4 + T, CD8 + T, CD19 + B, NK, and NKT cells and they recovered quickly after the drug was stopped. The plasma ICAM level was decreased and IL-10 was increased by fingolimod. Interestingly, fingolimod protected vascular permeability as indicated by a decreased plasma level of MMP9 and the reduced rT1%. In conclusion, modulation of systemic inflammation by fingolimod demonstrates that it is an effective therapeutic agent for ICH. Fingolimod may prevent perihematomal edema enlargement by protecting vascular permeability.
INTRODUCTION
Intracerebral hemorrhage (ICH) accounts for 10%-15% of all strokes worldwide and affects more than 2 million people each year [1, 2] . Its rate of incidence is 24.6 per 100 000 per year and this is expected to double by 2050 due to the increasing elderly population [3] [4] [5] . ICH is particularly severe as it is associated with a mortality rate of 30%-50% [6] . The high rate of mortality and morbidity likely results from a lack of proven medical treatment [1, 7] . Both the initial hematoma and the secondary perihematomal edema (PHE) contribute to the high mortality and morbidity. Most patients are able to survive the primary injury caused by the initial hematoma, but suffer severe neurological deficits caused by the secondary PHE injury. Increasing evidence has shown that inflammation plays a critical role in ICH-induced injury in the acute stage and the infl ammatory cascades contribute to the formation of edema that surrounds hematomas, exacerbate the mass effect, and amplify the cell death process via secondary ischemia [7] . Although progress has been made in identifying the roles of inflammatory signaling molecules, cells, and proteins in the initiation and progression of post-ICH infl ammation-mediated brain injury [5] , no therapies had been directed toward altering the inflammatory and edematous processes of this disease until our oral fi ngolimod trial in ICH [8] .
Fingolimod (FTY720) was the fi rst FDA-approved oral drug for multiple sclerosis treatment; it depletes circulating lymphocytes by preventing their migration from lymph nodes to the circulating pool [9] , thus possibly preventing their infiltration of the central nervous system (CNS).
In our recent trial, oral fingolimod in ICH (2-arm proofof-concept clinical trial: Fingolimod for the treatment of intracerebral hemorrhage) [8] [5, 6, 10] . In addition, as infl ammation may play quite different roles in the early (injury) and delayed phases (neuroregeneration) after ICH, the purpose of this study was to further determine the impact of fingolimod on the dynamic changes in plasma levels of inflammatory mediators and on lesion vascular permeability.
MATERIALS AND METHODS

Participants
This study was a two-arm, evaluator-blinded clinical trial of oral fi ngolimod for ICH patients at a dose of 0.5 mg per day for 3 consecutive days, the initial administration being within 1 h after the baseline computed tomographic (CT) scan and no later than 72 h after the onset of symptoms.
Twenty-three ICH patients with well-matched clinical characteristics, hematoma location, and volume as defi ned by CT, were assigned into control and fi ngolimod groups, 
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RESULTS
Fingolimod Dynamically Decreased Circulating Immune Cells in the Acute Stage
In this study, we found a reduction of NK and NKT cells per milliliter from (0.27 ± 0.24) ×10 6 and (0.08 ± 0.07) ×10 6 at T-0 to (0.14 ± 0.08) ×10 6 (P = 0.01) and (0.02 ± 0.01) ×10 to baseline at T-7 ( Fig. 1) . With circulating immune cells decreased, neutrophils in the peripheral blood (leukocyte subsets were assessed by standard laboratory differential white blood cell counts) were decreased at T-3 compared to the control (4.6 ± 0.6 vs 7.5 ±1.2, 10 6 /mL, P <0.001).
Fingolimod Differentially Affects Systemic Cytokine Secretion in the Acute Stage
During fingolimod treatment, the plasma concentration of ICAM-1 was notably lower in ICH patients at T-3 compared to the baseline (P <0.05) and the control group (P <0.01), and then returned to baseline at T-7. However, no signifi cant changes were found in the plasma levels of proinfl ammatory IL-6 and IL-21 after fi ngolimod treatment (Fig. 2 ). Interestingly, the plasma level of the antiinflammatory cytokine IL-10 was increased at day 3 after the fi rst dose of fi ngolimod (P <0.05) (Fig. 2) .
Reduction of Vascular Permeability in Fingolimod-
Treated ICH Patients
The presence of parenchymal enhancement on CET1-WI is a generally accepted indicator of contrast medium leakage across the disrupted blood-brain barrier (BBB). Here, we further evaluated the vascular permeability based on the CET1-WI images collected in previous clinical trials [8] . We found that parenchymal enhancement of the PHE was much greater in the control group (rT1%, 40.6 ± 3.0) than in the fi ngolimod group (20.5 ± 6.7) on day 7 after onset (P <0.001, Fig. 3A , B).
MMP9 is used as a plasma indicator of BBB disruption.
In this study, we found that MMP9 was notably lower with fingolimod treatment 1 day after the first dosage than baseline (P = 0.03) and the control group (P <0.01). This effect was sustained until 3 days after the first dosage (P = 0.01 compared with baseline). The plasma MMP9 level returned to baseline at day 7 after onset ( Fig. 3C ).
DISCUSSION
PHE is closely associated with post-stroke infl ammation [7] .
Inflammation is an important host-defense response to brain injury after ICH. The activation of innate immunity following ICH results in microglial activation, perihematomal inflammation reactions, infiltration of blood-derived infl ammatory cells including leukocytes, macrophages, and T cells [5, 7, 11, 12] , and release of infl ammatory cytokines [13, 14] .
Major orchestrators of this infl ammatory process are bloodderived immune cells, traffi cking from the periphery to the brain parenchyma [15, 16] . In patients, peripheral immune cells start to infiltrate the brain between 6 and 12 h after the occurrence of symptoms, and the number of braininfiltrating immune cells is positively correlated with neuronal apoptosis [17] .
Having determined that fingolimod attenuates neurological deficits, promotes recovery, and has therapeutic potential for preventing secondary brain injury in ICH [8] , we sought to understand how peripheral lymphocytes and cytokines are dynamically affected in these patients.
Previously, we demonstrated that oral fi ngolimod reduces the counts of CD4 + T, CD8 + T, and CD19 + B cells by 75%, 63%, and 83% respectively [8] .
In this study, we showed that fingolimod treatment not only restricted the numbers of circulating T-lymphocytes, but also NK, NKT, B cells, and neutrophils in the acute stage. Although stroke-induced immunosuppression syndrome has been identified in many studies [18] , the fi ngolimod treatment group had fewer immune cells than the control group, suggesting a direct preventive effect of fi ngolimod on lymphocyte entry into the circulating pool. And all the subsets of lymphocytes quickly returned to the baseline level after cessation of fi ngolimod administration. These results suggested a rapid and shortterm effect of fi ngolimod on the circulating lymphocyte pool that is beneficial for disease recovery, as inflammation in the early stage may cause brain injury, while the inflammatory milieu could promote neuroregeneration in the recovery stage [19] . Thus, this short period of fi ngolimod administration may have a less adverse effect of immune suppression [18] . Also, this rapid recovery of immune cells may benefit the neuroregeneration in the later stages of ICH. While circulating immune cells decreased, neutrophils in the fingolimod-treated group were normal, but lower than the control level. Studies on the natural course of leukocytes in ICH have reported that they increase after ICH, peak at 72 h, and almost disappear at 3 to 7 days, and these are associated with early neurological deterioration.
Both human studies [20] and animal experiments have reported increased numbers of leukocytes at the fi rst 72 h after onset [21] ; however, here we found that the leukocyte count in the fingolimod-treated group was significantly lower on day 3 than the control, according with better clinical improvement.
Post-cerebral hemorrhage systemic inflammation, characterized by elevated plasma levels of inflammatory mediators, is correlated with both ICH severity and poor clinical outcome [5, 6, 10] . To investigate the effect of fi ngolimod on infl ammatory mediators, we focused on ICAM-1, IL-21, IL-6, and IL-10. ICAM-1 is an important adhesion molecule that promotes leukocyte infiltration [20] [21] [22] . In this trial, our data suggested that fingolimod inhibited secretion and and the mass effect of the hemorrhage [23] . In this study, the unchanged levels of the proinflammatory cytokines IL-6
and IL-21 may contribute to the effectiveness of fi ngolimod and this phenomenon suggests a therapeutic effect. In addition, the plasma level of IL-10, an anti-inflammatory cytokine, signifi cantly increased 3 days after the fi rst dose of fingolimod, and returned to baseline when PHE was relieved.
We also observed a reduction in the volume of PHE in our clinical trial [8] . However, the mechanisms need further study. Disruption of the BBB was the fi rst issue to be further evaluated. CET1-WI has been used routinely in cerebral stroke studies [24] ; the presence of parenchymal enhancement on CET1-WI is generally accepted as an indicator of contrast medium leakage across the disrupted BBB. The timeline for BBB disruption has been shown to include initiation on day 1, a peak on days 5-7, and can last 14 days or longer [25, 26] . Therefore, here we evaluated the microvascular permeability on day 7. Hematoma within the brain parenchyma triggers a series of events leading to secondary injury and severe neurological deficits.
Although inflammation is triggered to remove blood and other residual debris, the by-products of this response are cytotoxic and lead to further tissue damage, BBB disruption, and edema. MMP9 has been widely implicated as a proinfl ammatory mediator of the development of BBB damage in cerebral hemorrhage. The signifi cant reduction of rT1% in this study indicated a strong protective effect of fi ngolimod on the BBB. MMP9 is a plasma indicator of BBB disruption both in animal models [27, 28] and in human patients [25, 26] . It has also been reported that, among patients with deep ICH, a n increase of MMPs is associated with PHE and the worsening of neurological defi cits in the acute stage [29] . The mechanism of this effect may be summarized as follows: direct damage of brain cells, cell injury by processing death molecules, disruption of myelin, and the conversion of pre-forms of inflammatory molecules into mature forms that perpetuate infl ammation. In this study, we further analyzed the plasma level of MMP9. Interestingly, the MMP9 levels signifi cantly decreased starting from day 1 after the first dose of fingolimod and persisted to day 3, but returned to baseline on day 7. This result strongly indicated that fingolimod protected against BBB damage through the reduced MMP9. Since the role of MMP in ICH recovery is still controversial, given its desirable effect on neurogenesis, myelin formation, and axonal growth [30, 31] , the recovery of MMP9 levels on day 7 may be promising for potential benefi ts on later neurogenesis.
In conclusion, in this trial of oral fingolimod on ICH, 
